![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase I Study of the Recombinant Immunotoxin LMB-2 in Patients With Tac-Expressing Leukemias and Lymphomas
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Published Results Related Publications Trial Contact Information Registry Information
Alternate Title
Immunotoxin in Treating Patients With Leukemia or Lymphoma
Basic Trial Information
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
Phase
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
Type
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
Status
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
Age
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
Sponsor
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
Protocol IDs
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
Phase I
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
Treatment
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
Completed
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
18 and over
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
NCI
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
NCI-96-C-0064F NCI-T95-0042N, T95-0042, NCT00002765
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
|
Objectives - Assess the therapeutic efficacy and toxicity of the recombinant immunotoxin LMB-2, an anti-Tac murine monoclonal antibody fragment conjugated to a truncated portion of Pseudomonas exotoxin, in patients with Tac-expressing leukemias and lymphomas.
- Define the pharmacokinetics of LMB-2, including the terminal elimination serum half-life, area under the curve, and volume of distribution.
- Evaluate, in a preliminary manner, the immunogenicity of LMB-2 in these patients.
- Determine the effect of LMB-2 on various components of the circulating cellular immune system.
Entry Criteria Disease Characteristics:
- Histologically confirmed Hodgkin's disease, non-Hodgkin's lymphoma, or leukemia in one of the following categories:
- Adult T-cell leukemia or lymphoma (ATL)
- No smoldering ATL
- No limitation on prior therapy
- Cutaneous T-cell lymphoma (CTCL)
- Stages IB-III and failed at least 1 standard therapy
- Stage IV regardless of prior therapy
- Stages I-IV peripheral T-cell lymphoma
- Relapsed after standard chemotherapy
- Ineligible for or refused salvage chemotherapy or bone
marrow
transplantation (BMT)
- B-cell non-Hodgkin's lymphoma (NHL) of any histology
- Indolent stages II-IV NHL
- Failed at least 1 standard therapy
- Disease symptomatic and requiring treatment
- Aggressive NHL
- Relapsed after standard chemotherapy
- Ineligible for or refused salvage chemotherapy or BMT
- Chronic lymphocytic leukemia (CLL)
- Rai stages III and IV or Binet stage C
- Failed standard therapy and at least 1 salvage
chemotherapy
- Primary B-cell prolymphocytic leukemia or
prolymphocytic transformation of
CLL
- Failed standard therapy and at least 1 salvage
chemotherapy
- Hairy cell leukemia
- Failed standard and salvage chemotherapy
- Ineligible for or refused further salvage chemotherapy
or BMT
- Acute myelogenous leukemia
- Failed standard chemotherapy
- Ineligible for or refused salvage chemotherapy or BMT
- Stages II-IV Hodgkin's disease
- Failed standard chemotherapy
- Ineligible for curative salvage radiotherapy or
chemotherapy
- Ineligible for or refused BMT
- Patients with leukemias or lymphomas not easily
classified in above categories who have failed standard therapy and are
ineligible for or have
refused bone marrow transplant
- Evidence of interleukin-2 receptor-alpha (IL2Ra) expression by one of the
following:
- Greater than 10% of malignant cells reactive with
anti-Tac by
immunohistochemistry
- Greater than 10% of malignant cells from a particular
site positive by FACS
- Greater than 400 IL2Ra sites per malignant cell by
radiolabeled anti-Tac
binding
- Soluble IL2Ra level greater than 1,000 U/mL (normal
geometric mean 235, with
95% confidence levels of 112-502 U)
- Hodgkin's disease with measurable disease not amenable
to biopsy
- No CNS disease requiring treatment
- Malignant cells in CSF allowed if judged not to
represent clinically
significant leukemic or lymphomatous meningitis (as
in CSF contamination by
blood)
Prior/Concurrent Therapy:
Biologic therapy: - See Disease Characteristics
- At least 3 weeks since prior interferon
Chemotherapy: - See Disease Characteristics
- At least 3 weeks since prior cytotoxic chemotherapy
- At least 3 weeks since prior retinoids
- No concurrent chemotherapy
Endocrine therapy: - No concurrent corticosteroids unless begun at least 3 weeks
prior to entry and dose not increased during 3 weeks prior to
entry
Radiotherapy: - See Disease Characteristics
- At least 3 weeks since prior whole-body electron beam
radiotherapy
- Other radiotherapy allowed within 3 weeks of entry provided
less than 10% of marrow irradiated and measurable disease exists outside
radiation port
Surgery: Other: - See Disease Characteristics
- At least 3 weeks since any prior systemic therapy
- No other concurrent investigational agents
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - Absolute neutrophil count greater than 1,000/mm3*
- Platelet count greater than 50,000/mm3*
[Note: *nonleukemic patients] Hepatic: - AST and ALT less than 5 times normal
Renal: - Creatinine less than 2.0 mg/dL
OR - Creatinine clearance greater than 50 mL/min
Pulmonary: - FEV1, TLC, and DLCO greater than 50% of predicted if pulmonary
or mediastinal involvement with tumor greater than one third of
total thoracic diameter
Other: - HIV negative
- Not pregnant
- Fertile patients must use effective contraception
- Serum must neutralize no more than 75% LMB-2 in tissue
culture
Expected Enrollment A maximum of 40 patients will be accrued for this study. Outline This is a dose escalation study. Patients receive LMB-2 immunotoxin IV over 30 minutes on days 1, 3, and
5. Treatment repeats every 15-21 days for up to 10 courses in the absence of
disease progression, neutralizing antibodies, or unacceptable toxicity. Cohorts of 3-6 patients each receive escalating doses of LMB-2
immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is
defined as the dose at which no more than 1 patient experiences dose limiting
toxicity. Published ResultsKreitman RJ, Wilson WH, White JD, et al.: Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18 (8): 1622-36, 2000.[PUBMED Abstract] Kreitman RJ, Wilson WH, Robbins D, et al.: Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 94 (10): 3340-8, 1999.[PUBMED Abstract] Related PublicationsKreitman RJ, Margulies I, Stetler-Stevenson M, et al.: Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 6 (4): 1476-87, 2000.[PUBMED Abstract] Robbins DH, Margulies I, Stetler-Stevenson M, et al.: Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin Cancer Res 6 (2): 693-700, 2000.[PUBMED Abstract]
Trial Contact Information
Trial Lead Organizations NCI - Center for Cancer Research ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) | Robert Kreitman, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | PHASE I STUDY OF ANTI-TAC(Fv)-PE38 (LMB-2), A RECOMBINANT SINGLE-CHAIN IMMUNOTOXIN FOR TREATMENT OF TAC-EXPRESSING MALIGNANCIES | ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 1996-04-24 | ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00002765 | ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 1996-04-24 | ![](https://webarchive.library.unt.edu/eot2008/20081017095005im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2003-03-19 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](images/spacer.gif) |